1. Insulet will present at the Goldman Sachs Healthcare Conference in June 2025. 2. The Omnipod Insulin Management System simplifies insulin delivery for diabetes patients. 3. Omnipod 5 integrates with glucose monitors and allows smartphone control. 4. Insulet positions its technology for subcutaneous drug delivery beyond insulin.
Insulet's ongoing innovations, particularly with Omnipod, are likely to attract investor interest, similar to prior positive market reactions to product presentations.
The announcement of a major healthcare event suggests potential partnership or product updates that could significantly impact market perception and stock value.
Successful presentations can bolster confidence and drive stock performance beyond the immediate term, as seen in previous healthcare conferences boosting stock prices post-announcement.
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 in Miami on Tuesday, June 10, 2025 at 9:20 a.m. (Eastern Time).
To listen to the live audio webcast of the presentation, please visit investors.insulet.com/events. A replay of the webcast will also be available following the event.
About Insulet Corporation:
Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet’s flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be controlled by a compatible personal smartphone in the U.S. or by the Omnipod 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, visit Insulet.com or omnipod.com.
©2025 Insulet Corporation. Omnipod is a registered trademark of Insulet Corporation. All rights reserved.